Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
| Autor: | Mario G Pavez Giani, Jan-Luuk Hillebrands, Silke U. Oberdorf-Maass, Dirk J. van Veldhuisen, Harry van Goor, Herman H W Silljé, Salva R. Yurista, Rudolf A. de Boer, Elisabeth-Maria Schouten, B. Daan Westenbrink |
|---|---|
| Přispěvatelé: | Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Groningen Institute for Organ Transplantation (GIOT) |
| Rok vydání: | 2018 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty Myocardial Infarction Renal function 030204 cardiovascular system & hematology Ventricular Function Left 03 medical and health sciences chemistry.chemical_compound Ventricular Dysfunction Left 0302 clinical medicine Glucosides Internal medicine medicine Empagliflozin Animals Myocardial infarction Benzhydryl Compounds Sodium-Glucose Transporter 2 Inhibitors Heart Failure Ejection fraction Ventricular Remodeling business.industry medicine.disease Rats medicine.anatomical_structure Treatment Outcome chemistry Ventricle Echocardiography Heart failure Cardiology Cardiology and Cardiovascular Medicine business Energy Metabolism EMPA |
| Zdroj: | European Journal of Heart Failure, 21(7), 862-873. Wiley |
| ISSN: | 1879-0844 1388-9842 |
| Popis: | AIMS: Sodium-glucose co-transporter 2 (SGLT2) inhibition reduces heart failure hospitalizations in patients with diabetes, irrespective of glycaemic control. We examined the effect of SGLT2 inhibition with empagliflozin (EMPA) on cardiac function in non-diabetic rats with left ventricular (LV) dysfunction after myocardial infarction (MI).METHODS AND RESULTS: Non-diabetic male Sprague-Dawley rats underwent permanent coronary artery ligation to induce MI, or sham surgery. Rats received chow containing EMPA that resulted in an average daily intake of 30 mg/kg/day or control chow, starting before surgery (EMPA-early) or 2 weeks after surgery (EMPA-late). Cardiac function was assessed using echocardiography and histological and molecular markers of cardiac remodelling and metabolism were assessed in the left ventricle. Renal function was assessed in metabolic cages. EMPA increased urine production by two-fold without affecting creatinine clearance and serum electrolytes. EMPA did not influence MI size, but LV ejection fraction (LVEF) was significantly higher in the EMPA-early and EMPA-late treated MI groups compared to the MI group treated with vehicle (LVEF 54%, 52% and 43%, respectively, all P CONCLUSION: Empagliflozin favourably affects cardiac function and remodelling in non-diabetic rats with LV dysfunction after MI, associated with substantial improvements in cardiac metabolism and cardiac ATP production. Importantly, it did so without renal adverse effects. Our data suggest that EMPA might be of benefit in heart failure patients without diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text